Beam Therapeutics Inc (BEAM) Price

BEAM Trial Data Boosts Sickle Cell Therapy Valuation

Beam Therapeutics reported positive new data from its BEACON trial for risto-cel, a therapy for sickle cell disease, demonstrating significant clinical improvements. A preliminary valuation analysis suggests a potential $65 per share value for the company's lead assets, signaling renewed momentum.